mohd izzuan Exelixis ( NASDAQ: EXEL ) revised its 2024 revenue projection upward after reporting Q3 financial results that beat on both lines . The biotech now sees 2024 revenue $2.15B-$2.
2B, up from $1.975B-$2.075B previously.
Consensus is $2.05B. Exelixis said it was boosting its 2024 guidance.